** Shares of drugmaker Eyenovia fall 52.5% to 16 cents premarket
** Co to discontinue a late-stage study for its experimental drug-device combination after it failed the main goal of slowing the progression of the condition
** Co was testing the drug to treat pediatric progressive myopia that causes near-sightedness in early childhood, which worsens as the person grows
** Says an independent committee reviewed the safety and efficacy data from 252 trial participants and found that the rate of myopia progression was not significantly different between the treatment arm and placebo
** "We plan to terminate the study, review the data more thoroughly, and evaluate next steps"- EYEN
** Says it is evaluating its strategic options, which may include a business combination, reverse merger, asset sales or a combination of those alternatives
** Up to last close, stock was down 83.7% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。